Glycomimetics Inc

-

Stock Issuer and Owners

Home | Sign Up | Log In
Due Diligence for Asset Managers
You have viewed 7 of the 10 daily limit
Subscribe for $29/month to gain full access
New Features
Latest Fund Raises
Related People
Fund Service Providers
Startup & Company Raises
List of Funds
Boston Firms
Boston Hedge Funds
Cornell Alumni Firms
CalPERS Portfolio
NYSCRF Portfolio
User Guide
Regulatory AUM vs AUM
LP Portfolios
Related Firms
Build a Portfolio
Comprehensive Search
Keyboard
Glycomimetics Inc
TickerCBIO
CIK #0001253689
CUSIPG2545C104
SectorLife Sciences - Pharmaceutical Preparations
Address401 Professional Drive, Suite 250, Gaithersburg, MD 20879
Source [EDGAR]
Reg D Offering (Form D) Filed Raised Terms
Glycomimetics Inc 2009-11-04 39.0 M Exemption: 506 · Remaining: $11,020,588 · Duration: One year or less · Revenue: Decline to Disclose
CIK Filing 2011 - 2026
[0001253689] 10-K
[0001253689] 10-Q
[0001253689] 3
[0001253689] 4
[0001253689] 5
[0001253689] 8-K
[0001253689] SC 13D
[0001253689] SC 13G
Form 13D/13G Filer Form 13D/13G Subject Filed % Owned
Balyasny Asset Management LP Crescent Biopharma Inc [2026-05-15] 0.0
Vestal Point Capital LP Crescent Biopharma Inc [2026-02-17] 0.0
Forgrowth III PA BV Crescent Biopharma Inc [2025-12-11] 0.0
Tang Capital Management LLC Crescent Biopharma Inc [2025-10-09] 0.0
1Globe Capital LLC Crescent Biopharma Inc [2025-08-20] 0.0
FMR LLC Crescent Biopharma Inc [2025-07-08] 0.0
Fairmount Funds Management LLC Glycomimetics Inc [2025-06-23] 0.0
Venrock Healthcare Capital Partners III LP Glycomimetics Inc [2025-06-23] 0.0
Logos Global Management LP Glycomimetics Inc [2024-11-27] 7.8
RA Capital Management LP Glycomimetics Inc [2024-11-06] 0.9
Adage Capital Management LP Glycomimetics Inc [2024-11-04] 7.9
Weinstein Benjamin Glycomimetics Inc [2024-08-14] 0.0
Artal International SCA Glycomimetics Inc [2023-02-13] 12.5
Vanguard Group Inc Glycomimetics Inc [2021-02-10] 5.37
EcoR1 Capital LLC Glycomimetics Inc [2020-07-20] 6.7
Biotechnology Value Fund L P Glycomimetics Inc [2019-08-15] 5.1
Camber Capital Management LP Glycomimetics Inc [2019-08-15] 2013.0
Invesco Ltd Glycomimetics Inc [2019-06-10] 11.0
Price T Rowe Associates Inc /MD/ Glycomimetics Inc [2019-02-14] 8.0
BlackRock Inc Glycomimetics Inc [2019-02-08] 6.6
OppenheimerFunds Inc Glycomimetics Inc [2018-09-06] 10.28
FMR LLC Glycomimetics Inc [2018-02-13] 0.0
Biotechnology Value Fund L P Glycomimetics Inc [2016-06-27] 4.7
Franklin Resources Inc Glycomimetics Inc [2016-02-05] 5.3
Wellington Management Co LLP Glycomimetics Inc [2014-02-10] 10.79
New Enterprise Associates 10 L P Glycomimetics Inc [2014-01-23] 50.3
Form 3/4/5 Filer 2011 - 2026
Scalzo Richard William
Crescent Biopharma Inc
Bispham Barbara Harlin
Im Ellie Eunkyung
McNeill Jonathan
Brumm Joshua T
Lynch Ryan
Pinkas Jan
Kiselak Tomas
Fairmount Funds Management LLC
Harwin Peter Evan
Fairmount Healthcare Fund II LP
Violin Jonathan
Moran Susan
Balcom Alexandra
Lubner David Charles
Doughty Christopher Grant
BVF Inc/IL
Biotechnology Value Trading Fund OS LP
BVF Partners L P/IL
Lampert Mark N
BVF GP Holdings LLC
BVF II GP LLC
BVF Partners OS Ltd
Biotechnology Value Fund L P
Biotechnology Value Fund II LP
BVF I GP LLC
Invus Public Equities Advisors LLC
Invus Public Equities LP
Debbane Raymond
Invus Global Management LLC
Siren LLC
Rock Edwin
Hahn Brian M
Jackson Scott Thomas
Andrews Patricia S
King Rachel K
Koenig Scott
Pearson Timothy R
Goldberg Mark Alan
Junius Daniel M
Rath Chinmaya
Johnson Bruce S
Semerjian Harout
Artal Group S A
WestEnd SA
Stichting Administratiekantoor WestEnd
Artal International SCA
Wittouck Amaury
Artal International Management SA
Sandell Scott D
Magnani John L
Girard Armand
Feldman Eric Jay
Thackray Helen M
Barrett M James
Barris Peter J
NEA Partners 10 L P
New Enterprise Associates 10 L P
Baldwin John J
Top Franklin H Jr
Henos Michael A
Kerins Patrick J
Viswanathan Ravi
Weller Harry R
Baskett Forest
Kolluri Krishna Kittu
NEA 13 GP Ltd
NEA Partners 13 Limited Partnership
New Enterprise Associates 13 LP
Drant Ryan D
Mott David M
Gust William M
Sanofi
Insider Transaction (Form 3/4/5) Date Action Shares Price Value ($)
Lynch Ryan
Ordinary Shares
2025-12-15 Grant 8,378
Pinkas Jan
Ordinary Shares
2025-12-15 Grant 17,507
Doughty Christopher Grant
Ordinary Shares
2025-12-15 Grant 14,714
Doughty Christopher Grant
Ordinary Shares
2025-12-15 Grant 8,000
Brumm Joshua T
Ordinary Shares
2025-12-15 Grant 45,117
Brumm Joshua T
Ordinary Shares
2025-12-15 Grant 10,000
Scalzo Richard William
Ordinary Shares
2025-12-15 Grant 14,422
Scalzo Richard William
Ordinary Shares
2025-12-15 Grant 5,000
McNeill Jonathan
Ordinary Shares
2025-12-15 Grant 19,507
McNeill Jonathan
Ordinary Shares
2025-12-15 Grant 6,000
Im Ellie Eunkyung
Ordinary Shares
2025-12-15 Grant 5,000
Im Ellie Eunkyung
Ordinary Shares
2025-12-15 Grant 16,298
Lynch Ryan
Ordinary Shares
2025-12-15 Grant 4,000
Bispham Barbara Harlin
Ordinary Shares
2025-12-15 Grant 6,000
Bispham Barbara Harlin
Ordinary Shares
2025-12-15 Grant 12,422
Pinkas Jan
Stock Option (Right to Buy) · derivative
2025-12-15 Grant 70,025 $0.00
Doughty Christopher Grant
Stock Option (Right to Buy) · derivative
2025-12-15 Grant 58,855 $0.00
Brumm Joshua T
Stock Option (Right to Buy) · derivative
2025-12-15 Grant 180,467 $0.00
Scalzo Richard William
Stock Option (Right to Buy) · derivative
2025-12-15 Grant 57,688 $0.00
McNeill Jonathan
Stock Option (Right to Buy) · derivative
2025-12-15 Grant 78,029 $0.00
showing 20 of 200 most recent transactions
13F Ownership Over TimeHoldersShares Held
2026-03-31 63 25,949,547
2025-12-31 58 24,103,244
2025-09-30 41 11,318,902
2025-06-30 31 10,751,780
2025-03-31 1 22
2024-12-31 1 15
2023-12-31 1 66
2023-09-30 33 2,166,502
2023-06-30 30 2,283,308
2023-03-31 41 3,391,980
2022-12-31 37 5,030,841
2022-09-30 37 7,883,928
Form 13F Holdings
Firm Period DFND Voting Shares
Y-Intercept Hong Kong Ltd [2026-06-30] SOLE 50,824 50,824
Fortitude Family Office LLC [2026-06-30] SOLE 40 40
Prev | Page 1 | Next
Terms | Privacy | Providers | Companies | Guide
tony@aum13f.com